Given time, ongoing mutation of the SARS-COV2 virus is likely to produce a super-lineage, at least as transmissible as the Delta variant and more resistant to current vaccines and monoclonal antibodies aimed at different targets in the receptor binding domain of the spike protein. A variety of candidate antibody therapeutics, insensitive to mutations found in major variants, may prove critical in the fight against COVID-19.
This paper cell.com/cell-reports/pdf/S... describes one such candidate antibody. It is highly technical. I don't know whether there is anything new in the technology, but the results should encourage others to prospect for therapeutic antibodies in the serum of recovered Covid patients.
"Here, we report a panel of SARS-CoV-2 antibodies... from an individual who recovered from COVID-19. Of these antibodies, 54042-4 shows potent neutralization against authentic SARS-CoV-2 viruses, including variants of concern (VOCs). A cryoelectron microscopy (cryo-EM) structure of 54042-4 in complex with the SARS-CoV-2 spike reveals an epitope composed of residues that are highly conserved in currently circulating SARS-CoV-2 lineages. Further, 54042-4 possesses uncommon genetic and structural characteristics that distinguish it from other potently neutralizing SARS-CoV-2 antibodies. Together, these findings provide motivation for the development of 54042-4 as a lead candidate to counteract current and future SARS-CoV-2 VOCs".